# Bioextrax > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/bioextrax). ## Overview Bioextrax is a Swedish biotechnology company that develops process technologies for producing bioplastics from renewable raw materials and for extracting protein and microfibers from feathers. The company was founded in 2014 on research from Lund University and operates as a technology developer and licensor rather than a large-scale manufacturer. ## Products & services • PHA bioplastic production processes • Feather protein extraction processes • Feather microfiber production processes • Licensing of proprietary bioprocess technologies • Process development using renewable feedstocks - **PHA bioplastic technology** (55%) — Biobased process technology for producing biodegradable PHA polymers from renewable inputs. - **Feather protein extraction** (20%) — Processes that recover protein from feathers for use in feed and other applications. - **Feather microfiber production** (10%) — Technology for producing microfibers from feathers for industrial and material uses. - **Licensing and commercialization services** (15%) — Licenses and related commercialization agreements for Bioextrax technologies. - PHA bioplastic production processes - Feather protein extraction processes - Feather microfiber production processes - Licensing of proprietary bioprocess technologies - Process development using renewable feedstocks ## Customers Bioextrax sells primarily to industrial partners that want to commercialize its process technologies through licensing agreements. Its customer base includes chemical companies, materials producers, and other manufacturers seeking lower-energy, lower-chemical routes to biobased materials. The feather-based technologies also point to potential customers in feed and ingredient markets that can use recovered protein and fibers. - **Chemical and materials companies** (primary) — They license PHA process technology to produce biodegradable plastics at commercial scale. - **Industrial commercialization partners** (primary) — They evaluate and adopt Bioextrax processes for pilot plants and first commercial facilities. - **Feed and ingredient markets** (secondary) — They use feather-derived protein as an input for feed or related applications. - **Materials and specialty product developers** (secondary) — They use feather microfibers or biobased outputs in niche industrial applications. - Chemical and materials companies licensing PHA process technology - Industrial partners evaluating pilot and commercial-scale deployment - Manufacturers seeking renewable feedstock-based process routes - Feed and ingredient users interested in feather protein outputs - Partners that need lower-energy, chemical-free bioprocesses ## Geography Bioextrax is headquartered in Sweden and its technology base is tied to Lund University research. The business is global in commercial ambition because its licensing model targets industrial partners outside Sweden, but the reports provided do not disclose a country revenue split. - Headquartered in Sweden - Research roots in Lund University - Commercial partners may be located internationally - Licensing model supports cross-border deployment - No country revenue split disclosed in the excerpts ## Strategy Bioextrax’s strategy is to commercialize its platform through multiple licensing agreements and partner-led scale-up rather than building a capital-intensive manufacturing footprint. It aims to expand the number of customers and collaborators using its PHA and feather-processing technologies, while proving that the processes can be deployed at industrial scale. - **Commercialize through licensing** (short-term) — Licensing fits the company’s technology model and avoids heavy manufacturing investment. - **Scale PHA process adoption** (medium-term) — PHA is the core bioplastic application and the main route to industrial relevance. - **Broaden partner base** (medium-term) — More partners increase validation, revenue opportunities, and technology reach. - Expand commercial licensing agreements - Convert technical validation into industrial deployments - Use partner-led scale-up to limit capital intensity - Broaden applications across PHA and feather-derived outputs - Position the technology as lower-cost and lower-impact ## Risks Bioextrax depends on converting technical development into signed licenses and partner adoption, so commercialization risk is central to the business. As a development-stage licensor, it also faces funding risk if recurring license revenue does not grow fast enough to support operations, alongside typical scale-up and execution risks in new bioprocess technologies. - **Commercialization and adoption risk** [high] — Revenue comes mainly from licensing, so delays in partner conversion directly affect income. - **Funding and liquidity risk** [high] — The company may need external capital if license income is insufficient to fund operations. - **Scale-up and technical execution risk** [high] — Industrial partners must validate and implement the processes at commercial scale. - **Competitive technology risk** [medium] — Alternative bioplastic and protein-recovery technologies may offer lower cost or easier deployment. - Revenue depends on successful licensing and partner adoption - Insufficient cash generation could require external financing - Scale-up risk if industrial partners delay or change plans - Technology commercialization may take longer than expected - Competition from alternative bioplastic and extraction methods ## Accounting Bioextrax’s reported revenue is driven mainly by license income, so timing of contract recognition can materially affect quarterly results. The company also has meaningful period-to-period volatility in costs and cash flow, which makes interim comparisons sensitive to the timing of commercialization milestones, grants, and partner activity. - **License revenue recognition** — Quarterly revenue can shift with new agreements and milestones - **Other operating income** — Can distort comparability with license revenue - **Going-concern assessment** — Affects disclosure and investor assessment of liquidity risk - **Cash flow volatility** — Makes interim cash generation difficult to extrapolate - License revenue timing affects quarterly reported sales - Grant income and other operating income can vary by period - Cash flow is volatile because commercialization is uneven - Personnel and external costs move with development activity - Going-concern assessment depends on funding and revenue timing --- *Last updated: 2026-08-11T04:04:51.230482+00:00*